がん免疫、細胞・遺伝子治療、酵母/ファージディスプレイ、ハイブリドーマ・B細胞、分子デザイン。Genedata Biologics®は、抗体、二重特異性抗体、抗体薬物複合体（ADC）、T細胞受容体（TCR）、キメラ抗原受容体（CAR-T）、アデノ随伴ウイルス（AAV）をはじめとするあらゆるバイオ医薬品の創薬業務に対応できるよう設計されており、導入後すぐに利用できます。
Genedata Biologics gives all our R&D groups a central place to record and access TCR-related information in real time, along the end-to-end workflow, including Immatics’ ACTengine, ACTallo and TCER bispecific TCR molecule development.
Genedata Biologics, tracks all biologics molecules from early discovery to development, and gives the UCB R&D organization central access to all relevant information on these molecules.
As part of our strategy to expand our biopharmaceutical R&D operations, we are implementing Genedata as our central workflow backbone to streamline our large-molecule R&D processes.
We chose Genedata Biologics because it is the only end-to-end software platform able to fully support our diverse and data-intensive workflow.
Pfizer is pleased to gain full access to this system for antibody discovery and protein engineering.
We determined that Genedata Biologics was the best solution to fully address all our unique workflow requirements as it enables scale up of the screening, engineering, production and testing of complex multi-specific antibody candidates.
The Biologics Data Platform makes the highly interconnected biologics R&D processes more efficient.
We thoroughly surveyed the market and selected what we think is the leading antibody R&D workflow platform.
The new Request Management System has made our overall biologics R&D process much more efficient – intergroup communication is now standardized, streamlined and traceable, and there is much less ad hoc communication.
